Skip to main content

Table 2 Number of patients who developed CMV episode(s) within 12 months of transplant according to donor (D) and recipient (R) CMV serology

From: Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients

Pre-transplant CMV serology

Total number (%)

Number (%) of patients who developed CMV episode(s)

0

1

≥2

D−/R-

58 (28%)

55 (26.4%)

1 (0.5%)

2 (1.0%)

D−/R+

59 (28.5%)

28 (13.5%)

19 (9.1%)

12 (5.8%)

D+/R-

20 (9.5%)

15 (7.2%)

4 (1.9%)

1 (0.5%)

D+/R+

71 (34%)

40 (19.2%)

20 (9.6%)

11 (5.3%)

Total

208 (100%)

138 (66.4%)

44 (21.2%)

26 (12.5%)